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Studies of families who segregate BRCA2 mutations have found that men who carry disease-associated mutations have an increased
risk of prostate cancer, particularly early-onset disease. A study of sporadic prostate cancer in the UK reported a prevalence of 2.3%
for protein-truncating BRCA2 mutations among patients diagnosed at ages p55 years, highlighting the potential importance of this
gene in prostate cancer susceptibility. To examine the role of protein-truncating BRCA2 mutations in relation to early-onset prostate
cancer in a US population, 290 population-based patients from King County, Washington, diagnosed at ages o55 years were
screened for germline BRCA2 mutations. The coding regions, intron–exon boundaries, and potential regulatory elements of the
BRCA2 gene were sequenced. Two distinct protein-truncating BRCA2 mutations were identified in exon 11 in two patients. Both
cases were Caucasian, yielding a mutation prevalence of 0.78% (95% confidence interval (95%CI) 0.09–2.81%) and a relative risk
(RR) of 7.8 (95%CI 1.8–9.4) for early-onset prostate cancer in white men carrying a protein-truncating BRCA2 mutation. Results
suggest that protein-truncating BRCA2 mutations confer an elevated RR of early-onset prostate cancer. However, we estimate that
o1% of early-onset prostate cancers in the general US Caucasian population can be attributed to these rare disease-associated
BRCA2 mutations.
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Studies of families segregating BRCA2 mutations (BCLC, 1999;
Johannsson et al, 1999; Eerola et al, 2001; Tulinius et al, 2002;
Bermejo and Hemminki, 2004; van Asperen et al, 2005), kin-cohort
studies of cancer incidence among relatives of population-based
breast or ovarian cancer cases (Loman et al, 2003; Risch et al,
2006), as well as studies of populations who harbour founder
BRCA2 mutations (Sigurdsson et al, 1997; Struewing et al, 1997,
Kirchhoff et al, 2004) suggest that men who carry a disease-
associated BRCA2 allele have an increased relative risk (RR) of
prostate cancer (two- to five-fold elevation). Two of the family
studies in which data were stratified on age at diagnosis of prostate
cancer reported that the RR was even higher (seven- to eight-fold
increase) in men diagnosed before age 65 years (BCLC, 1999; van
Asperen et al, 2005). These findings suggest that protein-
truncating BRCA2 mutations may play a role in prostate cancer
susceptibility. However, the majority of studies that have
investigated the role of BRCA2 mutations in hereditary prostate
cancer (HPC) families, which usually include men diagnosed with
prostate cancer at younger ages, have reported no disease-
associated mutations (Wilkens et al, 1999; Gayther et al, 2000;
Sinclair et al, 2000; Agalliu et al, 2007).
To date, only one study has assessed the contribution of BRCA2
mutations in early-onset sporadic prostate cancer (Edwards et al,
2003). In a case series of 263 men in the UK diagnosed with
prostate cancer at younger ages (p55 years), and who were not
selected on the basis of either breast or prostate cancer family
history, the prevalence of protein-truncating BRCA2 mutations
was 2.3% (95% confidence interval (95%CI) 0.8–5.0%) (Edwards
et al, 2003). The estimated RR of prostate cancer was 23.0 (95%CI
9.0–57.0) among protein-truncating BRCA2 mutation carriers in
that study. The main goal of the current study was to determine the
frequency of germline protein-truncating BRCA2 mutations in
early-onset prostate cancer patients in a US population.
MATERIALS AND METHODS
Study population
Case patients (n¼290) included in this analysis are Caucasian and
African American men diagnosed with histologically confirmed
adenocarcinoma of the prostate before age 55 years and who
participated in one of two population-based case–control studies
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sof prostate cancer conducted in King County, Washington. Case
patients in the first study (n¼168) were diagnosed from January 1,
1993 to December 31, 1996 (Stanford et al, 1999), and those in the
second study (n¼128) were diagnosed from January 1, 2002 to
December 31, 2005. Incident cases in both studies were identified
through the population-based Seattle-Puget Sound SEER cancer
registry, which also provided information on Gleason score,
tumour stage, and serum prostate-specific antigen (PSA) level at
diagnosis. Case patients completed a structured in-person inter-
view that collected information about demographic and lifestyle
characteristics, medical history, prostate cancer screening history,
and family history of prostate cancer and other cancers. After the
interview, patients were asked to provide a blood sample.
A total of 429 eligible prostate cancer case patients aged o55
years were identified during the ascertainment periods. Of eligible
patients, 381 (89%) were interviewed and 301 (79%) provided a
blood sample. A total of 290 case patients with adequate amounts
of DNA were sequenced for BRCA2 mutations. The study was
approved by the Institutional Review Board of the Fred
Hutchinson Cancer Research Center and the National Human
Genome Research Institute, and written informed consent was
obtained from all study participants.
BRCA2 gene sequencing
Genomic DNA was purified from peripheral blood lymphocytes
using a standard proteinase K digestion and alkaline lysis followed
by phenol–chloroform extraction (Sambrook et al, 1989). All
coding and non-coding regions of the BRCA2 gene were screened
for mutations using 47 primer pairs described previously (Malone
et al, 2000, 2006; Agalliu et al, 2007). Exons 5 and 6 were amplified
in a single fragment and longer exons were amplified using
multiple PCR reactions. There were five amplicons for exon 10
(10A–10E), 16 for exon 11 (11A–11P), and two for each of the
following exons: 14 (14A and 14B), 18 (18A and 18B), and 27 (27A
and 27B). PCR reactions were performed in a 10ml volume
containing 5ng of genomic DNA, 1mM dNTPs, 1.5mM, or 2.5mM
MgCl2,1 mM of both the forward and reverse primers, and 0.25U
Amplitaq DNA polymerase (Applied Biosystems, Foster City, CA,
USA).
PCR products were treated using the ExoSAP-IT method (USB
Corporation, Cleveland, OH, USA). DNA-sequencing reactions
were carried out using BigDye
s Terminator v3.1 Cycle Sequencing
Kits (Applied Biosystems, Foster City, CA, USA) and sequence data
were obtained on both forward and reverse PCR primers using the
ABI 3730xl Genetic Analyzer (Applied Biosystems, Foster City, CA,
USA). Contigs were assembled using PhredPhrap/Consed (Gordon
et al, 1998). Variants were detected using Polyphred (Nickerson
et al, 1997) and MutationSurveyor (http://www.softgenetics.com/
mutation Surveyor.html) by two independent researchers. All
variants were unanimously confirmed.
Statistical analyses
The 95% CI for the prevalence of protein-truncating BRCA2
mutations among prostate cancer patients was computed using a
Poisson-distributed events-table under the assumption that these
mutations are rare and follow a Poisson distribution. The
prevalence of germline protein-truncating BRCA2 mutations in
the general population was taken from a recently published study
of US women aged 35–64 years (Malone et al, 2006), and was used
to estimate the RR of prostate cancer in men aged o55 years
associated with carrying a BRCA2 mutation.
A w
2 test was used to evaluate whether the distribution of
genotypes for single nucleotide polymorphisms (SNPs) in the
BRCA2 gene differed by race (Caucasians vs African Americans),
family history of prostate cancer (yes vs no) or clinical
characteristics such as Gleason score (2–6 or 7¼3þ4 vs
7¼4þ3 or 8–10), stage of cancer (localised vs regional or
distant) or a composite measure of disease aggressiveness. The
definition of more aggressive prostate cancer included a Gleason
score of 7¼4þ3 or 8–10 or regional or distant stage or serum
PSA X20ngml
 1 at prostate cancer diagnosis; men with a Gleason
score of 2–6 or 7¼3þ4 and local stage tumours and a serum
diagnostic PSA level o20ngml
 1 at diagnosis were classified as
having less aggressive cancer. SAS version 9.1 (SAS Institute, Cary,
NC, USA) was used for statistical analyses.
RESULTS
Table 1 shows characteristics of the 290 population-based prostate
cancer patients screened for BRCA2 mutations; 11% were African-
American and 2% were Jewish. The proportion of patients that
reported either a first- or second-degree family history of prostate,
breast, or ovarian cancer was 37, 16, and 3%, respectively. Five
percent reported a family history of prostate, breast, and/or
ovarian cancers; 3% reported first-degree relatives with either
prostate or breast cancers. Most of the patients (79%) reported that
they had received at least one PSA test and/or digital rectal
examination (DRE) in the 5-year period before diagnosis. The
majority of the patients had localised tumours (73%), Gleason
scores of 2–6 (59%), and 36% of them were classified as having
tumours with more aggressive clinical features at diagnosis.
Two distinct protein-truncating BRCA2 mutations were identi-
fied, yielding an overall prevalence of 0.69% (95%CI 0.08–2.49%).
Table 2 shows characteristics of the two prostate cancer patients
with protein-truncating BRCA2 mutations. One of these mutations
was a 5-bp deletion (4625_4629delACATT) and the other was a
2-bp deletion (4074_4075delGT), both located in exon 11. Both
cases with protein-truncating BRCA2 mutations were Caucasian,
one reported a first-degree relative with prostate cancer, but
neither reported a family history of breast or ovarian cancer, and
both were diagnosed with Gleason score 7 tumours. As the protein-
truncating BRCA2 mutations were detected in Caucasians only,
the prevalence of such mutations in whites is 0.78% (95%CI
0.09–2.81%). Recently, Malone et al (2006) reported a weighted
prevalence of protein-truncating BRCA2 mutations of 0.1%
(95%CI 0.0–0.3%) among US population-based Caucasian control
women aged 35–64 years. Assuming that the prevalence of
disease-associated BRCA2 mutations among Caucasian men in
the general population is similar to the prevalence of such
mutations reported for US Caucasian women, the estimated RR of
prostate cancer in white men o55 years of age associated with
carrying a protein-truncating BRCA2 mutation is 7.78 (95%CI
1.80–9.37).
In addition to the two protein-truncating mutations, 84
sequence variants were detected in the BRCA2-coding exons,
intron–exon boundaries, and putative regulatory regions that were
sequenced. One SNP was in the 50 UTR region, 19 (22.6%) were
intronic SNPs, and 40 (47.6%) non-synonomous and 24 (28.6%)
synonomous SNPs were in coding exons. Most of these 84 SNPs
were rare; only 11 (13.1%) had a minor allele frequency of 3% or
greater, and of these, only four resulted in an amino-acid change
(Table 3). There were two SNPs that differed (Po0.05) between
Caucasian and African-American patients; both the C allele of SNP
1341A4C located in exon 10 and the T allele of the intronic SNP
(IVS17-14) were more common in white than African American
patients (26.7 vs 7.6% and 48.8 vs 34.8%, respectively). The
distribution of genotypes for the SNPs having a minor allele
frequency of X3% did not vary substantially according to family
history of prostate cancer or clinical features of the disease (data
not shown). One exception was that the frequency of the T allele
for the SNP 5971C4T located in exon 11 was higher in patients
with more aggressive disease in comparison to cases with less
aggressive clinical features, 5.2 vs 1.9%, respectively (P¼0.02).
BRCA2 mutations and early-onset prostate cancer
I Agalliu et al
827




















In this population-based study of 290 patients diagnosed with
prostate cancer before age 55 years, there were two patients with
germline protein-truncating BRCA2 mutations, yielding an overall
prevalence of 0.69% (95%CI 0.08–2.49%). One of the cases with a
BRCA2 mutation reported a first-degree relative with prostate
cancer, but neither reported a family history of breast or ovarian
cancer. As both disease-associated BRCA2 mutation carriers were
Caucasian, the prevalence of such mutations in whites is 0.78%
(95%CI 0.09–2.81%); the estimated RR of prostate cancer is 7.8
(95%CI 1.8–9.4) in Caucasian BRCA2 mutation carriers. Although
this represents a substantially elevated RR of earlier-onset prostate
cancer associated with carrying a germline protein-truncating
BRCA2 mutation, such mutations are very rare (B0.1%) in the
general US population (Malone et al, 2006). The estimated
cumulative risk (i.e. penetrance) of prostate cancer to age 55
years in Caucasian men due to carrying a disease-associated
BRCA2 mutation is about 1.1%, and the population attributable
risk of prostate cancer in this same group is 0.7%.
In a hospital-based series (n¼263) of prostate cancer patients
with early ages at diagnosis (p55 years) in the UK, Edwards et al
(2003) reported a prevalence of germline protein-truncating
BRCA2 mutations of 2.3% (95%CI 0.8–5.0%). The estimated RR
Table 1 Characteristics of 290 population-based prostate cancer patients aged o55 years at diagnosis screened for BRCA2 mutations
1993–1996 (n¼162) 2002–2005 (n¼128) Total case patients (n¼290)
Ascertainment period N % N % N %
Age at diagnosis (years)
35–49 39 24.1 58 45.3 97 33.4
50–54 123 75.9 70 54.7 193 66.6
Race
Caucasian 154 95.1 103 80.5 257 88.6
African-American 8 4.9 25 19.5 33 11.4
Jewish
No 159 98.1 126 98.4 285 98.3
Yes 3 1.9 2 1.6 5 1.7
Family history of prostate cancer
None 111 68.5 71 55.5 182 62.8
First-degree 33 20.4 40 31.3 73 25.2
Second-degree only 18 11.1 17 13.3 35 12.1
Family history of breast cancer
None 134 82.7 109 85.2 243 83.8
First-degree 22 13.6 15 11.7 37 12.8
Second-degree only 6 3.7 4 3.1 10 3.4
Family history of ovarian cancer
None 157 96.9 123 96.1 280 96.6
First-degree 2 1.2 3 2.3 5 1.7
Second-degree only 3 1.9 2 1.6 5 1.7
Prostate cancer screening
a
None 32 19.8 28 21.9 60 20.7
DRE only 46 28.4 25 19.5 71 24.5
PSA and DRE 84 51.9 75 58.6 159 54.8
Gleason score
2–4 19 11.7 — — 19 6.6
5–6 82 50.6 69 53.9 151 52.1
7 (3+4) 39 24.1 40 31.3 79 27.2
7 (4+3) 9 5.6 11 8.6 20 6.9
8–10 10 6.2 6 4.7 16 5.5
Missing 3 1.9 2 1.6 5 1.7
Stage of cancer
Localised 114 70.4 97 75.8 211 72.8
Regional 40 24.7 29 22.7 69 23.8
Distant 8 4.9 2 1.6 10 3.4
PSA at diagnosis (ng/ml)
b
0–3.9 26 16.1 29 22.7 55 19.0
4.0–9.9 77 47.6 63 49.2 140 48.3
10.0–19.9 21 12.9 15 11.7 36 12.4
X20 19 11.7 11 8.6 30 10.3
Missing 19 11.7 10 7.8 29 10.0
aOne or more prostate-specific antigen (PSA) test or digital rectal exam (DRE) in the 5-year period before diagnosis date.
bSerum prostate-specific antigen (PSA) level at
diagnosis.
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sof developing prostate cancer by age 56 years from a deleterious
germline BRCA2 mutation was 23.0 (95%CI 9.0–57.0). To compute
this RR estimate, Edwards et al (2003) used the average of the
estimated prevalence (i.e., 0.12 and 0.07%) of germline disease-
associated BRCA2 mutations in the general UK population, which
was indirectly estimated from two prior studies of breast cancer in
the UK (Peto et al, 1999; Antoniou et al, 2002). Interestingly, of the
six prostate cancer patients carrying disease-associated BRCA2
mutations, 50% were diagnosed before age 50 and most had no
family history of prostate cancer (five out of six) or breast cancer
(four out of six) (Edwards et al, 2003).
Although the overall finding is consistent with our results, a
lower prevalence of disease-associated BRCA2 mutations was
observed in our population-based patient series. This difference
may be due to different study designs and populations. Edwards
et al (2003) utilised prostate cancer patients recruited through
three different sources: Cancer Research UK/British Prostate
Group, UK Familial Prostate Cancer Study, and the British
Association of Urological Section of Oncology, and 90% of them
had clinically detected prostate cancer. By contrast, our patients
were ascertained from a population-based SEER registry. Most of
these men had received a PSA and/or DRE test within the 5-year
period before diagnosis, and 27% of the cases reported one or
more clinical signs or symptoms at the time of diagnosis.
Studies of families with breast and/or ovarian cancer who
harbour disease-associated BRCA2 mutations have reported that
male family members who carry such mutations have an increased
RR of prostate cancer (BCLC, 1999; Johannsson et al, 1999; Eerola
et al, 2001; Tulinius et al, 2002; Bermejo and Hemminki, 2004; van
Asperen et al, 2005). In the Breast Cancer Linkage Consortium
cohort of 173 breast and/or ovarian cancer families, a RR of 4.7
(95%CI 3.5–6.2) was reported for prostate cancer among BRCA2
Table 2 Characteristics of prostate cancer patients with germline
protein-truncating BRCA2 mutations
Case A Case B
BRCA2 mutation
Exon location 11 11
Nucleotide change 4625_4629delACATT 4074_4075delGT
Protein effect STOP 1467 STOP 1284
Characteristics
Age at diagnosis (years) 51 47
Race Caucasian Caucasian
Family history of
Prostate cancer Yes (first-degree) No
Breast cancer No No
Ovarian cancer No No
Clinical characteristics
Gleason score 7 (3+4) 7 (4+3)
Stage of cancer Localised Localised
PSA at diagnosis (ng/ml) Missing 6.3
















SNP in the 50 UTR region
202 G4A5 0 UTR GG 160 55.2 139 54.1 21 63.6 0.51
AG 100 34.5 90 35.0 10 30.3
AA 30 10.3 28 10.9 2 6.1
Non-synonomous SNPs
10 1092 A4C N289H AA 269 92.8 240 93.4 29 87.9 0.25
AC
b 21 7.2 17 6.6 4 12.1
10 1341 A4C N372H AA 170 58.6 142 55.3 28 84.8 0.004
AC 98 33.8 93 36.2 5 15.2
CC 22 7.6 22 8.6 — —
11 3198 A4G N991D AA 268 92.4 240 93.4 28 84.8 0.08
AG
b 22 7.6 17 6.6 5 15.2
11 5971 C4T T1915M CC 272 93.8 243 94.6 29 87.9 0.13
CT
b 18 6.2 14 5.4 4 12.1
Synonomous or intronic SNPs
10 1592 A4G S455S AA 269 92.8 240 93.4 29 87.9 0.25
AG
b 21 7.2 17 6.6 4 12.1
11 2456 T4C H743H TT 269 92.8 240 93.4 29 87.9 0.25
CT
b 21 7.2 17 6.6 4 12.1
11 3623 A4G K1132K AA 134 46.2 121 47.1 13 39.4 0.68
AG 121 41.7 105 40.9 16 48.5
GG 35 12.1 31 12.1 4 12.1
11 4034 T4C V1269V
c TT 195 67.2 171 66.5 24 72.7 0.72
CT 77 26.6 69 26.8 8 24.2
CC 16 5.5 15 5.8 1 3.0
14 7469 A4G S2414S AA 170 58.6 155 60.3 15 45.5 0.23
AG 104 35.9 89 34.6 15 45.5
GG 16 5.5 13 5.1 3 9.1
17 IVS17-14 T4C intronic CC 86 29.7 70 27.2 16 48.5 0.04
CT 134 46.2 123 47.9 11 33.3
TT 70 24.1 64 24.9 6 18.2
aw
2 P-value comparing the distribution of genotypes between Caucasian and African-American prostate cancer cases.
bNo homozygous variants were detected.
cTwo Caucasian
men had missing data for this SNP and thus percentages do not add up to 100%.
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sprotein-truncating mutation carriers (BCLC, 1999). In that study,
the RR was higher in men diagnosed at ages o65 years (RR¼7.3,
95%CI 4.7–11.5). A Finnish study (Eerola et al, 2001) of 107 breast
or ovarian cancer families reported a five-fold increase in the RR of
prostate cancer among men carrying protein-truncating BRCA2
mutations (RR¼4.9, 95%CI 1.8–11.0). Similar findings were
reported by Tulinius et al (2002) in an analysis of 995 breast
cancer pedigrees from Iceland. In that study, first-degree male
relatives of breast cancer patients carrying protein-truncating
BRCA2 mutations had a RR of 4.8 (95%CI 3.3–6.3) for prostate
cancer (Tulinius et al, 2002). Finally, van Asperen et al (2005) in a
analysis of 139 BRCA2 families from the Netherlands reported an
RR of 2.5 (95%CI 1.6–3.8) for prostate cancer among BRCA2
protein-truncating mutation carriers. When the analysis was
stratified by the age at diagnosis, the RR of prostate cancer was
8.0 (95%CI 4.1–14.0) among protein-truncating BRCA2 mutation
carriers diagnosed at ages o65 years.
In contrast to the above studies and the current analysis, most
studies of HPC families investigating the contribution of protein-
truncating BRCA2 mutations to prostate cancer susceptibility have
reported null results (Wilkens et al, 1999; Gayther et al, 2000;
Sinclair et al, 2000; Agalliu et al, 2007). Only one study conducted
in the UK of 38 affected individuals from HPC families with two to
five affected men per family reported a prevalence of 5.3% for
protein-truncating BRCA2 mutations (Gayther et al, 2000). In that
study, the two men with protein-truncating BRCA2 mutations were
diagnosed with prostate cancer at ages p56 years, and both had a
brother with prostate cancer. There is still uncertainty as to why
BRCA2 families, ascertained on the basis of members with breast
and/or ovarian cancer, have a higher RR of prostate cancer in men
carrying protein-truncating BRCA2 mutation (BCLC, 1999;
Johannsson et al, 1999; Eerola et al, 2001; Tulinius et al, 2002;
Bermejo and Hemminki, 2004; van Asperen et al, 2005). By
comparison, when HPC families that include members with a
history of breast or ovarian cancer are screened for BRCA2
mutations, no excess of protein-truncating BRCA2 mutations is
found (Agalliu et al, 2007).
A more complete understanding of the role of the BRCA2 gene in
relationship with prostate cancer susceptibility may provide insight
on prostate carcinogenesis. For example, the encoded BRCA2 protein
is involved in DNA repair, transcription, and cell cycle control
(Davies et al, 2001; Venkitaraman, 2002; Powell et al, 2003; Yoshida
and Miki, 2004). BRCA2 interacts directly with RAD51, which is an
essential protein for error-free double-strand DNA break repair by
homologous recombination (Sharan et al, 1997; Wong et al,1 9 9 7 ;
Xia et al, 2001; Pellegrini et al, 2002; Venkitaraman, 2002; Jackson,
2002; Powell et al, 2003). BRCA2 regulates both the intracellular
localisation and DNA-binding ability of RAD51, and therefore loss of
this control following BRCA2 inactivation may be a key event leading
to genomic instability and carcinogenesis (Davies et al,2 0 0 1 ;
Jackson, 2002; Yoshida and Miki, 2004). Whether prostate tissue is
particularly susceptible to BRCA2 loss is not clear. The fact that
protein-truncating mutations in the BRCA2 gene predispose to
breast and ovarian cancers suggests that the hormonal nature of
these cancers may be important. In relation to the prostate, a study
found that BRCA2 functions as a co-activator for the androgen
receptor (AR) in conjunction with histone acetyltransferase (Shin
and Verma, 2003). This finding suggests a novel mechanism by
which BRCA2 protein may exert its tumour suppressor function, by
altering AR signalling.
Our study has strengths and limitations that should be
considered when interpreting the results. The current study is
population-based; patients were not selected on the basis of
family history of prostate, breast, or ovarian cancer, which offers a
less-biased assessment of the role of BRCA2 protein-truncating
mutations in men from the general population. In addition,
this is one of the largest such studies completed to date. A
limitation of this study is that no screening for large genomic
deletions in the BRCA2 gene was performed, as this method
requires a relatively large amount of DNA per patient. It has been
estimated that large genomic deletions account for an additional
10–15% of reported disease-associated BRCA2 mutations (Szabo
and King, 1997). Thus, the prevalence of protein-truncating BRCA2
mutations might have been underestimated in this study. In
addition, owing to the high cost of genetic sequencing and the
rarity of germline BRCA2 protein-truncating mutations in the
general population, it was not feasible to screen the large number
of control men that would be required for direct case–control
comparisons. Therefore, we used the previously reported pre-
valence of BRCA2 mutations in Caucasian control women from the
general US population (Malone et al, 2006) to estimate the RR.
There is no reason to believe that the prevalence of BRCA2
mutations in the general population would be substantially
different between men and women, as the gene is located on
chromosome 13. Malone et al (2006) reported a prevalence of 0.1%
for germline BRCA2 protein-truncating mutations among US
Caucasian control women. This prevalence is similar to the
estimates of 0.12 and 0.07% for BRCA2 protein-truncating
mutations in the general UK population (Peto et al, 1999;
Antoniou et al, 2002). By contrast, a recent population-based
study of ovarian cancer in Ontario, Canada, estimated a higher
carrier frequency of protein-truncating BRCA2 mutations of 0.69%
(95%CI 0.43%–1.10%) in the general population (Risch et al,
2006). However, the Canadian estimate was based on data from
ovarian cancer patients. In addition, the ovarian cancer patient
population was enriched with subjects, such as Ashkenazi Jews,
known to have a higher prevalence of BRCA2 disease-associated
founder mutations (Risch et al, 2006).
In conclusion, the results of this study indicate that germline
protein-truncating mutations in the BRCA2 gene confer an
elevated RR (almost eight-fold) of developing early-onset prostate
cancer in Caucasian men. However, the population attributable
risk of prostate cancer in US Caucasians under age 55 due to
carrying one of these rare germline protein-truncating BRCA2
mutation is estimated to be o1%. Given the relatively high cost of
BRCA2 mutation screening and the rarity of these high-risk BRCA2
protein-truncating mutations in the general population, screening
for these mutations in the general population would not be cost
effective and is not currently recommended.
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